Mechanism of action

Thanks to Fluofarma, you can better understand your drugs and improve your chances of identifying a real blockbuster.

Benefits

A great number of pharmaceutical pipelines contain molecules (from leads through to Phase III trial compounds) whose mechanism of action remains poorly understood. However, understanding of the exact cellular mechanism of action is crucial for predicting the likelihood of side effects.

Signaling pathway analysis

Fluofarma's technology helps you visualize a drug's functional effects via the analysis of up to 130 different molecular events. With Fluofarma, you will be able to monitor all the molecular and cellular effects induced by your compounds.

Expertise

Fluofarma’s scientists are experts in cell signaling pathways and in drug discovery optimization. Our team will help you design appropriate studies for mapping the full extent of the cell signaling induced by your compounds.

 

Breaking news

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal Cell Research.

    Read more [+]

  • Publication

    Fluofarma cited in a Biocompare featured article “Flow Cytometry Gets a Makeover”

    Read more [+]

  • Press Release

    Roche adopts Fluofarma’s high-content screening platform.

    Read more [+]

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal "Analytical Chemistry".

    Read more [+]

  • ECCP 2010

    Fluofarma will be attending the European Cancer Cluster Partnering 2010 in Oslo, from September 15th to 17th.

    Read more [+]

  • BIO-Connexion Congress

    Fluofarma will be attending the Bio-Connexion Congress in Paris, from October 6th to 7th.

    Read more [+]

  • 22nd EORTC-NCI-AACR symposium

    Fluofarma will be exhibitor at the 22nd EORTC-NCI-AACR symposium in Berlin from November 16th to 19th.

    Read more [+]

Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into a multi-year agreement with Roche.
Read More



ALL NEWS